Scientists test 'Double Punch' immune therapy to stop tough lymphoma
NCT ID NCT05801913
Summary
This early-stage study is testing the safety and feasibility of a two-part treatment for aggressive B-cell lymphoma that has come back or is not responding to other therapies. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back. They also give a vaccine designed to help these modified cells last longer and work better to prevent the cancer from returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.